Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2

TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of
TSND-201 in PTSD